Latvija - latvijščina - Zāļu valsts aģentūra

teva b.v., netherlands - bortezomibs - pulveris injekciju šķīduma pagatavošanai - 3,5 mg

Latvija - latvijščina - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - metotreksāts - koncentrāts infūziju šķīduma pagatavošanai - 100 mg/ml

Latvija - latvijščina - Zāļu valsts aģentūra

hospira uk limited, united kingdom - docetaksels - koncentrāts infūziju šķīduma pagatavošanai - 10 mg/ml

Latvija - latvijščina - Zāļu valsts aģentūra

hospira uk limited, united kingdom - oksaliplatīns - koncentrāts infūziju šķīduma pagatavošanai - 5 mg/ml

Latvija - latvijščina - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - etopozīds - koncentrāts infūziju šķīduma pagatavošanai - 20 mg/ml

Latvija - latvijščina - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - irinotekāna hidrohlorīda trihidrāts - koncentrāts infūziju šķīduma pagatavošanai - 20 mg/ml

Latvija - latvijščina - Zāļu valsts aģentūra

fresenius kabi polska sp.z o.o., poland - paklitaksels - koncentrāts infūziju šķīduma pagatavošanai - 6 mg/ml

Evropska unija - latvijščina - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - imūnsupresanti - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Latvija - latvijščina - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - retinolum, colecalciferolum, skābes ascorbicum, thiamini nitras, tocopherylis acetas, kalcija pantothenas, pyridoxini hydrochloridum, riboflavinum, nicotinamidum, acid-folicum, cyanocobalaminum - apvalkotās tabletes

Latvija - latvijščina - Pārtikas un veterinārais dienests, Zemkopības ministrija

farmprodukt, ooo - tablete